QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.094375v1 316/2/481    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Quik, M. Articles by McIntosh, J. M. Search for Related Content PubMed PubMed Citation Articles by Quik, M. Articles by McIntosh, J. M.

PERSPECTIVES IN PHARMACOLOGY

Striatal 6^* Nicotinic Acetylcholine Receptors: Potential Targets for Parkinson's Disease Therapy

The Parkinson's Institute, Sunnyvale, California (M.Q.); and Departments of Biology and Psychiatry, University of Utah, Salt Lake City, Utah (J.M.M.)

The presence of distinct nicotinic acetylcholine receptor (nAChR) subtypes in specific central nervous system (CNS) areas offers the possibility of developing targeted therapies for diseases involving the affected brain region. Parkinson's disease is a neurodegenerative movement disorder characterized by a progressive degeneration of the nigrostriatal system. 6-containing nAChRs (designated 6^*1 nAChRs) have a relatively selective localization to the nigrostriatal pathway and a limited number of other CNS regions. In addition to a unique distribution, this subtype has a distinct pharmacology and specifically interacts with -conotoxinMII, a toxin key in its identification and characterization. 6^* nAChRs are also regulated in a novel manner, with a decrease in their number after nicotine treatment rather than the increase observed for 4^* nAChRs. Striatal 6^* receptors were functional and mediate dopamine release, suggesting that they have a presynaptic localization. This is further supported by lesion studies showing that both 6^* nAChR sites and their functions are dramatically decreased with dopaminergic nerve terminal loss, in contrast to only small declines in 4^* and no change in 7^* receptors. Although the role of nigrostriatal 6^* nAChRs is only beginning to be understood, an involvement in motor behavior is emerging. This latter observation coupled with the finding that nicotine protects against nigrostriatal damage suggest that 6^* nAChRs may represent unique targets for neurodegenerative disorders linked to the nigrostriatal system such as Parkinson's disease.

Address correspondence to: Dr. Maryka Quik, The Parkinson's Institute, 1170 Morse Ave, Sunnyvale, CA 94089-1605. E-mail: mquik{at}parkinsonsinstitute.org

This article has been cited by other articles:

				K. O'Leary, N. Parameswaran, J. M. McIntosh, and M. Quik Cotinine Selectively Activates a Subpopulation of {alpha}3/{alpha}6{beta}2 Nicotinic Receptors in Monkey Striatum J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 646 - 654. [Abstract] [Full Text] [PDF]

				L. Azam, D. Yoshikami, and J. M. McIntosh Amino Acid Residues That Confer High Selectivity of the {alpha}6 Nicotinic Acetylcholine Receptor Subunit to {alpha}-Conotoxin MII[S4A,E11A,L15A] J. Biol. Chem., April 25, 2008; 283(17): 11625 - 11632. [Abstract] [Full Text] [PDF]

				H. Walsh, A. P. Govind, R. Mastro, J. C. Hoda, D. Bertrand, Y. Vallejo, and W. N. Green Up-regulation of Nicotinic Receptors by Nicotine Varies with Receptor Subtype J. Biol. Chem., March 7, 2008; 283(10): 6022 - 6032. [Abstract] [Full Text] [PDF]

				J. S. Zeiger, B. C. Haberstick, I. Schlaepfer, A. C. Collins, R. P. Corley, T. J. Crowley, J. K. Hewitt, C. J. Hopfer, J. Lessem, M. B. McQueen, et al. The neuronal nicotinic receptor subunit genes (CHRNA6 and CHRNB3) are associated with subjective responses to tobacco Hum. Mol. Genet., March 1, 2008; 17(5): 724 - 734. [Abstract] [Full Text] [PDF]

				R. M. Drenan, R. Nashmi, P. Imoukhuede, H. Just, S. McKinney, and H. A. Lester Subcellular Trafficking, Pentameric Assembly, and Subunit Stoichiometry of Neuronal Nicotinic Acetylcholine Receptors Containing Fluorescently Labeled {alpha}6 and 3 Subunits Mol. Pharmacol., January 1, 2008; 73(1): 27 - 41. [Abstract] [Full Text] [PDF]

				A. Zanardi, R. Ferrari, G. Leo, U. Maskos, J.-P. Changeux, and M. Zoli Loss of high-affinity nicotinic receptors increases the vulnerability to excitotoxic lesion and decreases the positive effects of an enriched environment FASEB J, December 1, 2007; 21(14): 4028 - 4037. [Abstract] [Full Text] [PDF]

				T. Bordia, S. R. Grady, J. M. McIntosh, and M. Quik Nigrostriatal Damage Preferentially Decreases a Subpopulation of {alpha}6beta2* nAChRs in Mouse, Monkey, and Parkinson's Disease Striatum Mol. Pharmacol., July 1, 2007; 72(1): 52 - 61. [Abstract] [Full Text] [PDF]

				T. Bordia, N. Parameswaran, H. Fan, J. W. Langston, J. M. McIntosh, and M. Quik Partial Recovery of Striatal Nicotinic Receptors in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Monkeys with Chronic Oral Nicotine J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 285 - 292. [Abstract] [Full Text] [PDF]

				P. Tumkosit, A. Kuryatov, J. Luo, and J. Lindstrom beta3 Subunits Promote Expression and Nicotine-Induced Up-Regulation of Human Nicotinic {alpha}6* Nicotinic Acetylcholine Receptors Expressed in Transfected Cell Lines Mol. Pharmacol., October 1, 2006; 70(4): 1358 - 1368. [Abstract] [Full Text] [PDF]

				S. E. McCallum, N. Parameswaran, T. Bordia, H. Fan, J. M. McIntosh, and M. Quik Differential Regulation of Mesolimbic {alpha}3/{alpha}6beta2 and {alpha}4beta2 Nicotinic Acetylcholine Receptor Sites and Function after Long-Term Oral Nicotine to Monkeys J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 381 - 388. [Abstract] [Full Text] [PDF]